First-quarter fiscal 2010 results announced by Biomet

NewsGuard 100/100 Score

Biomet, Inc. announced today financial results for its first fiscal quarter ended August 31, 2009.

  • Net sales increased 4% (7% constant currency) to $630 million, with 9% growth in the U.S.
  • Reconstructive sales, excluding dental, increased 5% (9% constant currency) worldwide, with 10% U.S. growth
  • Knee sales increased 6% (10% constant currency) worldwide, with U.S. growth of 9%
  • Hip sales increased 2% (6% constant currency) worldwide, with 4% U.S. growth
  • Extremity sales increased 18% (23% constant currency) worldwide, and increased 39% in the U.S.
  • Spine sales increased 15% (17% constant currency) worldwide, with 15% U.S. growth

Net sales increased 4% during the first fiscal quarter ended August 31, 2009, to $630.1 million from $607.0 million for the first quarter of fiscal year 2009. Excluding the impact of foreign currency, net sales increased 7% during the first quarter.

U.S. sales increased 9% to $400.2 million during the quarter; Europe sales of $154.8 million decreased 9% (increased 3% constant currency); and International (primarily Canada, South America, Mexico and the Pacific Rim) sales increased 9% to $75.1 million (13% constant currency). Excluding dental and the impact of foreign currency, net sales during the first quarter of fiscal 2010 increased 9% worldwide, 10% in the U.S., 7% in Europe, and 10% for International.

During the first quarter of fiscal 2010, Biomet reported $113.0 million of special items (pre-tax), including purchase accounting charges of $98.4 million. The purchase accounting charges primarily relate to amortization expense for established intangible assets and depreciation expense as a result of the step-up of property to fair value. The remaining $14.6 million of special items included costs primarily related to the Company’s Operational Improvement Program and $5.2 million of stock compensation expense. A reconciliation of reported results to adjusted results is included in this press release, which is also posted on Biomet’s website:


Biomet, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Updated recommendations for management of people with hip and knee osteoarthritis